 |
|
New Guidelines for Treating Rheumatoid Arthritis
July 23, 2008BIRMINGHAM, Ala. - Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB).
Lead author Kenneth Saag, M.D., M.Sc., a professor in the UAB Division of Clinical Immunology and Rheumatology, said the new guidelines update strategies for treating RA with the goal of preventing joint damage and disability.
The new recommendations do not strive to replace individualized medical decisions, Saag said. Instead, they are meant to guide rheumatologists and other health care workers toward the most updated recommendations. The last set of American College of Rheumatology RA treatment guidelines was published in 2002. "The recommendations developed are not intended to be used in a 'cookbook' or prescriptive manner, or to limit a physician's clinical judgment," Saag said. "They provide guidance based on clinical evidence and expert panel input."
BIOLOGICS AND DMARDs
The recommendations focus on several classes of anti-arthritic drugs, including a potent group of agents called disease-modifying anti-rheumatic drugs (DMARDs). Newer genetically engineered DMARDs called biologics often work in combination with earlier therapies. Many anti-arthritic drugs are designed to stop damaging inflammation, and biologics work to interrupt the chain of events that leads to inflammation.
Newer biologics called anti-TNF agents - adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade)- prevent the production of an immunity protein that plays a role in inflammation.
Some of the key recommendations include:
* Methotrexate or leflunomide therapy is recommended for most RA patients.
* Anti-TNF agents etanercept, infliximab, or adalimumab along with methotrexate can be used in new or early RA cases with worsening and severe symptoms.
* Doctors should not initiate or resume treatment with methotrexate, leflunomide, or biologics if RA patients have active bacterial infection, shingles (herpes-zoster), hepatitis B, hepatitis C and active or latent tuberculosis.
* Doctors should not prescribe anti-TNF agents to patients with a history of heart failure, lymphoma or multiple sclerosis.
The full list of RA treatment recommendations is available at www.rheumatology.org by clicking on practice support, then guidelines.
University of Alabama at Birmingham
BIOLOGICS AND DMARDs
The recommendations focus on several classes of anti-arthritic drugs, including a potent group of agents called disease-modifying anti-rheumatic drugs (DMARDs). Newer genetically engineered DMARDs called biologics often work in combination with earlier therapies. Many anti-arthritic drugs are designed to stop damaging inflammation, and biologics work to interrupt the chain of events that leads to inflammation.
Newer biologics called anti-TNF agents - adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade)- prevent the production of an immunity protein that plays a role in inflammation.
Some of the key recommendations include:
* Methotrexate or leflunomide therapy is recommended for most RA patients.
* Anti-TNF agents etanercept, infliximab, or adalimumab along with methotrexate can be used in new or early RA cases with worsening and severe symptoms.
* Doctors should not initiate or resume treatment with methotrexate, leflunomide, or biologics if RA patients have active bacterial infection, shingles (herpes-zoster), hepatitis B, hepatitis C and active or latent tuberculosis.
* Doctors should not prescribe anti-TNF agents to patients with a history of heart failure, lymphoma or multiple sclerosis.
The full list of RA treatment recommendations is available at www.rheumatology.org by clicking on practice support, then guidelines.
University of Alabama at Birmingham
Rheumatology Current Events and Rheumatology News RSSChildhood wheezing with rhinovirus can increase asthma odds 10-fold
Infants who experience viral respiratory illnesses with wheezing are known to be at increased risk for developing asthma later during childhood.
Survival instincts propel 'difficult patient' to insist on quality care
Michelle Mayer had to become a "difficult patient" before she could get her physicians to accurately diagnose the disease that was destroying her health.
Pediatric researchers find possible 'master switch' gene in juvenile arthritis
Researchers have found that a gene region known to play a role in some varieties of adult rheumatoid arthritis is also present in all types of childhood arthritis. The researchers say the responsible gene may be a "master switch" that helps turn on the debilitating disease.
Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients
New data presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their methotrexate treatment regimen, with positive results sustained up to one year later.
Novel DNA microarray chip predicts functional impairment and remission in rheumatoid arthritis
A new DNA microarray chip can predict severe disability and remission in patients with rheumatoid arthritis (RA), as presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France. The chip (called the 'ARTchip') has yielded two clinical-genetic models of RA outcomes, to assist physicians in anticipating likely disease progression and prognosis and thereby guide decisions on the best course of treatment for individual patients.
Rheumatoid arthritis factors equal to cardiovascular factors in risk of severe cardiovascular events
Certain cardiovascular disease (CVD) risk factors and rheumatoid arthritis (RA) disease factors have a similar effect on an RA patient's risk of experiencing myocardial infarction (MI) or stroke.
CV risk management should be mandatory in RA and other types of inflammatory rheumatic disease
Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients should undergo compulsory cardiovascular (CV) risk management and existing CV risk calculators should be adapted to the increased CV risk in inflammatory rheumatic disease patients.
50 percent of recent onset RA patients become free of signs and symptoms within 36 weeks
At least 50% of recent onset rheumatoid arthritis patients achieve remission (a state free of signs and symptoms) within 36 weeks when following a systematic approach of step-up DMARD treatment in combination with tight control.
Most ongoing diabetes trials do not include outcomes important to patients
An analysis of ongoing randomized clinical trials (RCTs) in diabetes finds that only about 20 percent have as primary outcomes results that patients consider important, such as illness, pain, effect on function and death, according to a study in the June 4 issue of JAMA.
Landmark observational study aims to improve osteoporosis care standards worldwide
Nearly 60,000 women aged 55 years and older have enrolled in a landmark, multi-national study that will focus on the management of osteoporosis across the globe.
More Rheumatology Current Events and Rheumatology News Articles
 | Rheumatology Secrets by Sterling West The new and expanded second edition of this popular volume covers the common and uncommon rheumatic disorders encountered in practice, discussed on rounds, and found on exams. Each chapter reviews basic immunology and pathophysiology, important disease manifestations, and practical management issues. This edition features a new section on Pain Management. Mnemonics, lists, tables, illustrations... |
 | Current Diagnosis & Treatment in Rheumatology (Current Rheumatology) by John B. Imboden, David B. Hellmann, John Henry Stone Authoritative and clinically focused guidance in a clear, concise, find-it-now format Essential NEW MATERIAL INCLUDES: Updated review of NSAIDs in light of current controversies and developments Expanded coverage of rheumatoid arthritis Added material in the increasingly relevant area of clinical genetics More illustrations and radiographs New chapter on Pearls in Hospital... |
 | Kelley's Textbook of Rheumatology: 2-Volume Set, Expert Consult: Online and Print (Textbook of Rheumatology (Kelley's)(2 Vol)) by Gary S. Firestein, Ralph C. Budd, Edward D. Harris, Iain B. McInnes, Shaun Ruddy, John S. Sergent Staying current in a field that's advancing rapidly is difficult. Now more than ever, Kelley's Textbook of Rheumatology, 8th Edition helps you better understand today's scientific underpinnings of rheumatic diseases, so that you can better manage your patients. With its new full-color design, scholarly approach to scientific concepts, and sweeping updates, you'll have a source of knowledge at... |
 | Rheumatology: Questions and Answers by H. M., M.D. Adelman, John D. Carter, Joanne, M.D. Valeriano-Marcet, Keith S., M.D. Kanik, Mitchel J., M.D. Seleznick |
 | Harrison's Rheumatology Everything you would expect from Harrison's-and more! Featuring the contents of the Rheumatology section of Harrison's Principles of Internal Medicine, 16th Edition-enhanced with important updates, new and annotated references, new illustrations, and self-assessment/exam review Questions and Answers-this next-generation resource is perfect for the backpack, the wards, and in all clinical... |
 | Rheumatology e-dition: Text with Continually Updated Online Reference, 2-Volume Set (Rheumatology) by Marc C. Hochberg, Alan J. Silman, Josef S. Smolen, Michael E. Weinblatt, Michael H. Weisman This latest edition continues the tradition of excellence of previous editions with comprehensive, authoritative coverage of rheumatic disease from basic scientific principles to practical points of clinical management. Internationally renowned authors deliver essential information on the definition of a disease, epidemiology, pathophysiology, clinical findings, differential diagnosis, and... |
 | Pediatric Rheumatology in Clinical Practice by Patricia Woo, Ronald M. Laxer, David D. Sherry Pediatric Rheumatology in Clinical Practice is authored by a trio of experts from the UK, US and Canada. The book presents the physician with key points and summary boxes about various symptoms, making the book a useful quick reference guide. 79 illustrations, most of them in color, enhance the text. Pediatric Rheumatology in Clinical Practice will be of particular interest to rheumatologists... |
 | Atlas of Rheumatology by Gene G. Hunder (Editor) This edition of the Atlas of Rheumatology is designed to help clinicians learn about arthritis and other related musculoskeletal disorders and to develop an understanding of their possible clauses, clincal features, laboratory findings, and treatments in an informative, pictorial... |
| Thompson's Rheumatology Pocket Reference by Andrew E. Thompson | |
 | Little Black Book of Rheumatology (Little Black Book Series) by Marc L. Miller This pocket-sized handbook provides comprehensive, concise and evidence-based information on the diagnosis and treatment of rheumatic disease. The Little Black Book of Rheumatology is a convenient resource offering quick access to vital information and makes a great reference for solving pressing problems on the ward or in the clinic. Key Features of he Little Black Book of Rheumatology: ... |
| © 2008 BrightSurf.com |